Intellectual Property Licensing
•217 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (217)
| Company | Market Cap | Price |
|---|---|---|
|
ATOM
Atomera Incorporated
Atomera licenses MST intellectual property, generating revenue primarily through IP licensing and royalties.
|
$169.49M |
$5.33
+0.28%
|
|
LODE
Comstock Inc.
Strategic licensing of decarbonization technologies and related IP.
|
$160.46M |
$3.12
+2.46%
|
|
NLST
Netlist, Inc.
Netlist's core strategy is monetizing its IP portfolio through licensing revenues and patent damages.
|
$157.57M |
$1.78
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed engages in licensing and royalty arrangements for intellectual property (e.g., HTIT license), making Intellectual Property Licensing a relevant revenue/operational theme.
|
$154.43M |
$3.88
+0.52%
|
|
SAVA
Cassava Sciences, Inc.
Exclusive license agreement with Yale University — IP Licensing activity directly related to simufilam.
|
$154.10M |
$3.23
+1.10%
|
|
BYRN
Byrna Technologies Inc.
LATAM divestiture into licensing/distribution suggests material IP licensing revenue.
|
$150.99M |
$6.67
+6.21%
|
|
VTVT
vTv Therapeutics Inc.
The company relies on IP protection and licensing (e.g., Novo Nordisk background; patent allowance through 2041), fitting the 'Intellectual Property Licensing' theme as a core strategic asset.
|
$150.13M |
$37.73
+2.65%
|
|
DERM
Journey Medical Corporation
Journey Medical monetizes its intellectual property via licensing/out-licensing deals (e.g., Emrosi and other assets).
|
$146.26M |
$5.39
+4.26%
|
|
CTW
CTW Cayman Class A Ordinary Shares
CTW leverages IP-based anime content and licenses IP for game development, representing IP licensing activity.
|
$144.90M |
$2.27
+0.22%
|
|
IKT
Inhibikase Therapeutics, Inc.
Company holds intellectual property and licensing activities around its programs (IKT-001Pro and risvodetinib).
|
$137.57M |
$1.81
+6.76%
|
|
SKYX
SKYX Platforms Corp.
Intellectual property licensing for SKYX's plug-and-play technology (licensing revenue).
|
$133.09M |
$1.17
+3.54%
|
|
AOUT
American Outdoor Brands, Inc.
The company emphasizes IP protection and pending patents, enabling IP licensing activity.
|
$121.21M |
$9.53
+2.03%
|
|
RPTX
Repare Therapeutics Inc.
The company monetizes IP via licensing out platforms and assets (Intellectual Property Licensing).
|
$113.84M |
$2.65
-0.19%
|
|
ACOG
Alpha Cognition Inc. Common Stock
Alpha Cognition engages in IP licensing (e.g., ALPHA-1062 platform and Asia-Pacific rights).
|
$105.05M |
$6.50
+5.18%
|
|
HLVX
HilleVax, Inc.
Involves licensing of intellectual property related to vaccine candidates (e.g., HIL-216.00).
|
$104.79M |
$2.09
|
|
ANIX
Anixa Biosciences, Inc.
Licensing of biotech IP related to CAR-T and vaccine technologies.
|
$97.13M |
$2.92
+3.00%
|
|
WNDW
SolarWindow Technologies, Inc.
The company signals licensing and IP-driven partnerships as a path to commercialization, relevant to Intellectual Property Licensing.
|
$91.59M |
$0.35
|
|
TENX
Tenax Therapeutics, Inc.
Tenax holds exclusive rights to levosimendan in the US/Canada, a core IP/licensing aspect of its business model.
|
$90.22M |
$14.45
+7.20%
|
|
SGMO
Sangamo Therapeutics, Inc.
Licensing of STAC-BBB capsid and related IP provides non-dilutive funding and IP monetization.
|
$88.16M |
$0.25
-7.96%
|
|
FLCX
flooidCX Corp.
Intellectual property licensing is a key revenue stream via licensed distributorships and patent-pending tech.
|
$87.50M |
$0.00
|
|
CBUS
Cibus, Inc.
Business model includes licensing of gene-edited traits and IP to seed companies with royalty streams.
|
$86.31M |
$1.59
+11.54%
|
|
GAIA
Gaia, Inc.
Gaia retains worldwide rights to content/IP, enabling licensing to partners and platforms.
|
$73.32M |
$2.91
+5.43%
|
|
FBIO
Fortress Biotech, Inc.
Royalty/IP-based value streams (e.g., licensing-related milestones) align with Intellectual Property Licensing.
|
$73.25M |
$2.35
+0.21%
|
|
IBO
Impact BioMedical Inc.
Impact BioMedical monetizes its IP via licensing agreements, constituting Intellectual Property Licensing.
|
$67.48M |
$0.62
-5.97%
|
|
GCL
GCL Global Holdings Ltd Ordinary Shares
GCL monetizes game IP via publishing and licensing arrangements, including developing and licensing IP.
|
$65.58M |
$0.53
-1.21%
|
|
VHC
VirnetX Holding Corp
The company monetizes its patent portfolio through Intellectual Property Licensing.
|
$64.36M |
$15.48
+7.28%
|
|
LOOP
Loop Industries, Inc.
Revenue stream from licensing Loop's intellectual property and core technology.
|
$63.90M |
$1.31
+0.38%
|
|
VRDR
Verde Resources, Inc.
VRDR engages in IP licensing and technology transfer related to Verde Net Zero Blueprint and binder/biochar asphalt designs.
|
$58.45M |
$0.04
|
|
RMCO
Royalty Management Holding Corporation
RMCO monetizes through intellectual property licensing and royalty rights on technology and IP assets.
|
$57.94M |
$4.00
+0.63%
|
|
LNZA
LanzaTech Global, Inc.
The company licenses its proprietary gas fermentation technology, a form of IP licensing.
|
$52.37M |
$23.15
-35.52%
|
|
LVO
LiveOne, Inc.
Intellectual Property Licensing: monetization of LiveOne's IP and technology assets.
|
$51.63M |
$4.47
+2.05%
|
|
ZTEK
Zentek Ltd.
Zentek operates as an intellectual property technology development and commercialization company, implying IP licensing activities.
|
$51.47M |
$0.50
+0.38%
|
|
LEAT
Leatt Corporation
Leatt licenses its Leatt-Brace IP and earns royalty income from licensed products, representing an intellectual property licensing revenue stream.
|
$50.77M |
$9.35
|
|
IBIO
iBio, Inc.
iBio engages in Intellectual Property Licensing (e.g., exclusive rights licensed to AstralBio), a core monetization channel.
|
$46.32M |
$2.06
-2.61%
|
|
HOWL
Werewolf Therapeutics, Inc.
Global Jazz collaboration/licensing of JZP898 constitutes Intellectual Property Licensing activity.
|
$45.90M |
$0.94
+2.62%
|
|
LVTX
LAVA Therapeutics N.V.
LAVA engages in IP licensing and asset monetization (including CVRs and collaborations with Pfizer/J&J).
|
$45.77M |
$1.65
-5.17%
|
|
VNCE
Vince Holding Corp.
Licensing of Vince's brand IP constitutes a brand/IP licensing revenue stream.
|
$45.35M |
$3.35
+10.00%
|
|
GLXZ
Galaxy Gaming, Inc.
Galaxy Gaming licenses proprietary casino table game IP and related tech (e.g., Bonus Jackpot System) to operators; core IP licensing business.
|
$42.61M |
$1.93
|
|
RPMT
Rego Payment Architectures, Inc.
RPMT owns and licenses intellectual property/patents central to its platform technology.
|
$41.93M |
$0.34
|
|
SQNS
Sequans Communications S.A.
Sequans is building licensing revenue from its 5G IP, including TORUS/eRedCap, and ACP RF IP.
|
$41.01M |
$2.65
+1.34%
|
|
NIPG
NIP Group Inc.
Intellectual property licensing related to IP in the gaming/digital entertainment ecosystem.
|
$39.98M |
$0.70
-2.75%
|
|
BIOX
Bioceres Crop Solutions Corp.
HB4 trait licensing and royalty monetization imply an IP licensing business line.
|
$37.58M |
$0.60
-5.96%
|
|
PXLW
Pixelworks, Inc.
Pixelworks monetizes IP licensing for its proprietary visual processing technology.
|
$35.06M |
$5.54
+4.04%
|
|
NTIP
Network-1 Technologies, Inc.
NTIP's core business is acquiring and monetizing patents via licensing and settlements, i.e., Intellectual Property Licensing.
|
$34.23M |
$1.49
+1.71%
|
|
VPLM
Voip-Pal.com Inc.
VoIP-Pal monetizes a portfolio of VoIP-related patents primarily via licensing and patent enforcement, directly aligning with Intellectual Property Licensing.
|
$33.35M |
$0.01
|
|
ABVC
ABVC BioPharma, Inc.
ABVC engages in IP licensing through agreements and patents (e.g., Japan patent for ABV-1504) and partnerships.
|
$32.08M |
$1.33
+8.13%
|
|
CELU
Celularity Inc.
Celularity monetized IP and entered an exclusive, royalty-bearing license for the sold IP with a repurchase option.
|
$32.03M |
$1.15
-4.17%
|
|
REFR
Research Frontiers Incorporated
SPD-SmartGlass licensing is the core revenue model via IP licensing.
|
$31.30M |
$0.92
-2.15%
|
|
SNAL
Snail, Inc. Class A Common Stock
Intellectual property licensing of the ARK IP to related party and partners.
|
$31.14M |
$0.83
+9.07%
|
|
QSEP
QS Energy, Inc.
Temple University licenses underpinning the AOT technology imply an Intellectual Property Licensing aspect to the business.
|
$30.54M |
$0.10
|
|
NXTC
NextCure, Inc.
The company engages in licensing of its IP (e.g., SIM0505 outside territory), representing IP Licensing activities.
|
$27.67M |
$10.28
-6.55%
|
|
TOON
Kartoon Studios Inc.
Ownership and monetization of Stan Lee Universe and other IP assets through licensing.
|
$26.98M |
$0.57
+1.19%
|
|
NEON
Neonode Inc.
Neonode's core business is licensing its IP and monetizing via royalties.
|
$26.35M |
$1.58
+1.28%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria emphasizes its growing patent portfolio and licensing of its technology, indicating IP licensing as a core revenue stream.
|
$25.63M |
$1.02
+4.06%
|
|
MAXN
Maxeon Solar Technologies, Ltd.
The content highlights monetization of an extensive IP portfolio and licensing arrangements.
|
$25.23M |
$1.57
+3.97%
|
|
VTGN
VistaGen Therapeutics, Inc.
Company monetizes through licensing and sublicensing agreements, constituting an IP licensing business activity.
|
$24.79M |
$0.64
+5.52%
|
|
MSGM
Motorsport Games Inc.
MSGM owns proprietary IP (e.g., Le Mans Ultimate) and monetizes via IP licensing arrangements.
|
$24.79M |
$4.08
-4.12%
|
|
XCUR
Exicure, Inc.
License/royalty arrangements for cavrotolimod IP indicate Intellectual Property Licensing activity.
|
$24.14M |
$3.77
-2.28%
|
|
TXMD
TherapeuticsMD, Inc.
TXMD's core business model is licensing pharmaceutical IP and collecting royalties from partners for licensed women's health products.
|
$23.96M |
$2.10
+0.96%
|
|
LGVN
Longeveron Inc.
Longeveron licensed iPSC technology, representing Intellectual Property Licensing activity.
|
$23.47M |
$1.09
-0.45%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
NIH Patent License Agreement provides exclusive rights to NIH-derived IP related to LB-100, representing a material intellectual property licensing asset.
|
$20.59M |
$3.63
+12.73%
|
|
VYNE
VYNE Therapeutics Inc.
Company has an exclusive worldwide license for a BET inhibitor library, constituting Intellectual Property Licensing.
|
$20.16M |
$0.61
-1.05%
|
|
RAIN
Rain Enhancement Technologies Holdco Inc
The company relies on exclusive IP licensing for weather modification patents and related engineering designs.
|
$19.50M |
$2.57
|
|
APHP
American Picture House Corporation
Engages in IP licensing and related rights monetization (Intellectual Property Licensing).
|
$16.70M |
$0.14
|
|
NNUP
Nocopi Technologies, Inc.
NNUP licenses its reactive ink technologies and related IP, making Intellectual Property Licensing a core revenue channel.
|
$16.65M |
$1.50
|
|
GIGM
GigaMedia Limited
GigaMedia owns/provides IP rights for its games/platforms; IP licensing is a revenue stream.
|
$16.47M |
$1.36
-3.20%
|
|
NAII
Natural Alternatives International, Inc.
Licensing of NAII's proprietary beta-alanine IP (CarnoSyn, SR CarnoSyn, TriBsyn) generating licensing-related revenue.
|
$16.46M |
$2.71
+0.74%
|
|
KNW
Know Labs, Inc.
Intellectual property licensing as a primary strategic revenue channel via KTL.
|
$16.05M |
$2.14
|
|
SEED
Origin Agritech Limited
Significant licensing of biotechnology traits and IP (GMO/gene-editing assets) to partners, reflecting IP licensing activity.
|
$14.92M |
$1.28
+1.18%
|
|
APLT
Applied Therapeutics, Inc.
The company out-licensing AT-001 and engages in IP licensing arrangements for its assets, indicating intellectual property licensing activity.
|
$14.83M |
$0.11
+4.37%
|
|
AGAE
Allied Gaming & Entertainment Inc.
GAE holds and licenses intellectual property (e.g., Z-Tech IP, Angry Birds collaboration), creating an IP licensing business line.
|
$14.09M |
$0.37
+0.62%
|
|
LPCN
Lipocine Inc.
TLANDO is being commercialized through IP licensing agreements (e.g., Verity, regional partners), reflecting an Intellectual Property Licensing business model.
|
$13.49M |
$2.42
-5.27%
|
|
FGI
FGI Industries Ltd.
FlushGuard anti-overflow toilet technology is licensed, aligning with Intellectual Property Licensing.
|
$12.48M |
$6.62
+36.78%
|
|
PETV
PetVivo Holdings, Inc.
Licensing of IP related to Precise PRP suggests Intellectual Property Licensing as a revenue/strategy channel.
|
$11.56M |
$0.80
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Company holds exclusive worldwide licenses to drug programs/assets, representing IP licensing as a revenue/asset strategy.
|
$11.34M |
$1.00
-7.35%
|
|
XELB
Xcel Brands, Inc.
Licensing of intellectual property (brand IP) to licensees generating royalties.
|
$10.29M |
$2.12
+13.64%
|
|
AQMS
Aqua Metals, Inc.
Plans to license AquaRefining technology to partners, indicating IP licensing as a core growth vector.
|
$10.11M |
$7.18
-0.14%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Company has options to license QRX007 and QRX008; IP licensing is part of its business strategy.
|
$9.48M |
$6.42
-2.43%
|
|
ALDS
APPlife Digital Solutions, Inc.
Acquired LeSalon IP supports IP licensing and monetization.
|
$9.02M |
$0.00
|
|
DSS
DSS, Inc.
Company licenses intellectual property and technologies (IP Licensing) including AuthentiGuard and biotech assets.
|
$8.73M |
$0.93
-3.08%
|
|
ELVG
Elvictor Group, Inc.
Licensing of AI software/IP related to the crew management platform.
|
$8.29M |
$1.50
|
|
TSE
Trinseo PLC
Licensing income from polycarbonate technology shows a direct IP licensing revenue line.
|
$8.27M |
$0.23
+0.39%
|
|
CRIS
Curis, Inc.
Curis monetizes intellectual property via licensing (e.g., Hedgehog pathway tech and Erivedge royalties).
|
$7.80M |
$0.60
+1.42%
|
|
GELS
Gelteq Limited Ordinary Shares
The company licenses its patent-pending gel delivery technology to partners, making Intellectual Property Licensing a central revenue model.
|
$7.01M |
$0.74
-0.52%
|
|
BMRA
Biomerica, Inc.
Intellectual Property Licensing leveraging Biomerica's patent portfolio and licensing opportunities.
|
$6.58M |
$2.20
|
|
MGRX
Mangoceuticals, Inc.
Intellectual property licensing for acquired patents and technology.
|
$6.09M |
$0.45
-5.73%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Business model includes licensing of intellectual property (hCDR1) via collaborations (e.g., with Yeda).
|
$5.94M |
$2.66
+1.14%
|
|
VS
Versus Systems Inc.
Licensing Versus Systems' proprietary gamification and engagement technology as IP to ASPIS Cyber Technologies provides the licensing revenue.
|
$5.93M |
$1.15
-1.29%
|
|
SBFM
Sunshine Biopharma, Inc.
The company engages in exclusive intellectual property licensing arrangements with external entities.
|
$5.47M |
$1.17
-4.88%
|
|
PRKR
ParkerVision, Inc.
ParkerVision's core business is licensing and monetizing its RF patent portfolio, i.e., intellectual property licensing.
|
$5.29M |
$0.22
|
|
HCMC
Healthier Choices Management Corp.
HCMC monetizes its patent portfolio (Q-Cup, Imitine) through licensing and enforcement activities, constituting an Intellectual Property Licensing business line.
|
$5.27M |
$0.00
|
|
RVYL
Ryvyl Inc.
Intellectual Property Licensing; licensing of core technology/IP components to customers/partners.
|
$5.27M |
$5.81
-4.91%
|
|
ALBT
Avalon GloboCare Corp.
QTY code protein design IP constitutes an Intellectual Property Licensing asset with potential monetization value.
|
$5.14M |
$1.06
-20.52%
|
|
PULM
Pulmatrix, Inc.
The company monetizes its IP (iSPERSE and related assets) through licensing and royalties, a direct service/product offering.
|
$4.60M |
$1.24
-1.20%
|
|
CYCN
Cyclerion Therapeutics, Inc.
The company monetizes its intellectual property through licensing deals and milestone-based payments.
|
$4.14M |
$1.24
-0.40%
|
|
BUDZ
WEED, Inc.
Potential licensing of proprietary cannabis/genomics IP and related technologies.
|
$4.08M |
$0.03
|
|
GTCH
GBT Technologies Inc.
GTCH monetizes IP via licensing, including VisionWave patents; direct IP licensing activity.
|
$3.70M |
$0.00
|
|
HIGR
Hi-Great Group Holding Company
Exclusive worldwide IP licensing for KRAS gene assets represents a major monetization/licensing channel.
|
$3.18M |
$0.03
|
|
ATNF
ETHZilla Corporation Common Stock
Monetization of legacy biotech IP via licensing and maintenance.
|
$3.16M |
$5.24
|
|
ADN
Advent Technologies Holdings, Inc.
Intellectual Property Licensing is a primary revenue/strategic focus for Advent (licensing IP for MEA technology).
|
$2.45M |
$0.91
-0.65%
|
Showing page 2 of 3 (217 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
